

COPY

JC07 Rec'd PCT/PTO 17 JAN 2002

Attorney's Dock No. 06501-077001-04-A0004P-US

09/830548

#9/DA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Katsunari Tezuka et al.

Art Unit : Unknown

Serial No. : 09/830,548

Examiner : Unknown

Filed : April 26, 2001

Title : A PHARMACEUTICAL COMPOSITION FOR TREATING IMMUNE DISEASES

BOX PCT

Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated June 29, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

✓ AA₁ Insert the initial paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

Replace the paragraph beginning at page 4, line 18, with the following rewritten paragraph:

AA₂ The ligands for CD28 and CTLA-4 are CD80 (B7-1) and CD86 (B7-2) in human and mice. CTLA-4 has about 20 times as high affinity to both ligands as CD28. It has been

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL696752252US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

August 29, 2001

Signature

Typed or Printed Name of Person Signing Certificate